FY2025 Earnings Forecast for Icon Issued By Leerink Partnrs

Icon Plc (NASDAQ:ICLR) – Analysts at Leerink Partnrs reduced their FY2025 earnings per share estimates for Icon in a report released on Tuesday, August 12th. Leerink Partnrs analyst M. Cherny now expects that the medical research company will post earnings per share of $12.67 for the year, down from their previous estimate of $12.79. The consensus estimate for Icon’s current full-year earnings is $13.38 per share. Leerink Partnrs also issued estimates for Icon’s FY2026 earnings at $13.51 EPS, FY2027 earnings at $15.57 EPS and FY2028 earnings at $17.28 EPS.

Other research analysts have also recently issued reports about the company. UBS Group lifted their price objective on Icon from $170.00 to $240.00 and gave the company a “buy” rating in a research report on Friday, July 25th. JPMorgan Chase & Co. cut Icon from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $265.00 to $150.00 in a research report on Tuesday, April 29th. Robert W. Baird raised Icon from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $150.00 to $224.00 in a research report on Thursday, July 24th. Baird R W raised Icon from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 24th. Finally, Barclays lifted their price objective on Icon from $155.00 to $180.00 and gave the company an “equal weight” rating in a research report on Friday, July 25th. Six analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Icon has an average rating of “Moderate Buy” and a consensus price target of $219.54.

Icon Stock Up 0.3%

ICLR stock opened at $175.84 on Friday. Icon has a twelve month low of $125.10 and a twelve month high of $328.35. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.35. The stock has a market cap of $14.20 billion, a P/E ratio of 18.09, a PEG ratio of 2.60 and a beta of 1.17. The business’s 50-day moving average price is $156.14 and its 200-day moving average price is $160.21.

Icon (NASDAQ:ICLR) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $3.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.18 by $0.08. The business had revenue of $2.02 billion for the quarter, compared to analysts’ expectations of $1.98 billion. Icon had a return on equity of 10.95% and a net margin of 9.82%. The business’s revenue for the quarter was down 4.8% on a year-over-year basis. During the same period last year, the firm posted $3.75 earnings per share.

Institutional Trading of Icon

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Transcend Capital Advisors LLC increased its stake in Icon by 7.6% in the 1st quarter. Transcend Capital Advisors LLC now owns 1,174 shares of the medical research company’s stock worth $205,000 after acquiring an additional 83 shares during the last quarter. First National Bank Sioux Falls increased its stake in Icon by 5.7% in the 2nd quarter. First National Bank Sioux Falls now owns 1,580 shares of the medical research company’s stock worth $230,000 after acquiring an additional 85 shares during the last quarter. Mutual Advisors LLC increased its stake in Icon by 3.6% in the 2nd quarter. Mutual Advisors LLC now owns 2,698 shares of the medical research company’s stock worth $392,000 after acquiring an additional 93 shares during the last quarter. Hunter Perkins Capital Management LLC increased its stake in Icon by 0.4% in the 2nd quarter. Hunter Perkins Capital Management LLC now owns 22,399 shares of the medical research company’s stock worth $3,258,000 after acquiring an additional 97 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its stake in Icon by 22.8% in the 1st quarter. Farther Finance Advisors LLC now owns 593 shares of the medical research company’s stock worth $99,000 after acquiring an additional 110 shares during the last quarter. Institutional investors own 95.61% of the company’s stock.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.